HOME > BUSINESS > Alembic Pharma buys US-based generics manufacturer

Alembic Pharma buys US-based generics manufacturer

Alembic Pharmaceuticals said it bought New Jersey-based generic drug developer Orit Laboratories LLC, which will bring seven approved generics and four applications with it.

Orbit has “a team of eight highly experienced scientists,” Alembic said, adding that the firm focuses on developing and filing oral solid and liquid products.

“We Welcome Dr. Satish Patel, Founder and CEO of Orit, and his impressive team to the Alembic family,” said Pranav Amin, Managing Director of the Indian drug maker.

He said Dr Patel has proven expertise in the US generic pharmaceuticals industry, which will help Alembic.

Established in August 2005, Orit has a state-of-the-art 8,600 square feet R&D and pilot manufacturing facility, which has also been acquired.

“Apart from the existing ANDAs, Orit adds Complementary skill sets in soft gelatin based oral solids and oral liquids,” Alembic said.

“This acquisition expands our basket of product offerings to our customers, shows our commitment to be a long term player in the US generic industry, and will help us have a powerful R&D footprint in the US,” Amin added.

Mr R. K. Baheti, Alembic’s CFO said, “this tuck-in acquisition marks our first cross border transaction, especially reflecting our ambition to grow Alembic’s US generic business in a measured way which meets our internal hurdle rate.”

Dr. Satish Patel added, “I am very pleased that Orit is now a part of Alembic. I have personally and professionally known and admired Alembic as well as its Promoters the Amin family for a long time.”

With this acquisition, Alembic will now have a total of 69 ANDA (generic) approvals (61 final and 8 tentative) from the USFDA.

Financial details of the transaction were not disclosed.

Proximare Inc. acted as strategic advisors to Orit Laboratories LLC and Okner Realty, which sold the property on which the company was situated.

Follow ULTRA.news
Panacea Biotech, Serum Institute in polio vaccine tie-up Panacea Biotec said it signed two long-term agreements with the world's largest vaccine manufacturer, Serum Institute of India Pvt. Ltd, for manufacturing polio vaccines with a potential market size of $1.25 bln per year. The vaccine will also protect against six other diseas...
Ipca Laboratories acquires US pharma manufacturer for $9.65 mln Ipca Laboratories Ltd said it is has acquired US-based drug manufacturer Pisgah Labs Inc. for US$ 9.65 millions free of debt. The acquisition is aimed at establishing the company's foothold in the US market in the field of contract research and small-volume manufacturing of a...
Idea-Vodafone merger gets NCLT approval The proposed merger between Idea Cellular and Vodafone got the approval of India's National Company Law Tribunal, with the rider that the merged entity will be liable to pay income tax on behalf of Vodafone India in case of a ruling that Vodafone India has to pay the arrears. ...
NIIT acquires US-based corporate training firm NIIT Chairman Rajendra Pawar (center) NIIT Limited, which made a name for itself training millions of Indians with IT skills, said it acquired a US-based corporate training company. NIIT will incur a cost of $8.1 mln (Rs 51.50 cr) over the next five years for the acquisiti...
OrbiMed Asia invests $7.5 mln more in Vivimed Labs unit Vivimed Labs said it will receive $7.5mn investment from OrbiMed Asia into its API business as a follow on to the $42.5 mn invested in September 2017. At the time, Vivimed has said that the proceeds will be utilised for debt reduction at the parent entity level as well as for...
RCom confirms sale of telecom assets to Reliance Jio An RCom exhibition stall Reliance Jio, the firm led by Mukesh Ambani, will walk away with most of the telecom assets of Reliance Communications, led by Mukesh's brother Anil. Rcom said it has "signed definitive binding agreements with Reliance Jio Infocomm Limited for sale...
Bank of Baroda buys out Pioneer Investments from AMC unit Bank of Baroda said it will buy out its foreign partner Pioneer Investments in its asset management subsidiary to raise its stake in the unit to 100%. It will acquire 51% of Baroda Pioneer Asset Management Company for an undisclosed amount. This is being done due to the ac...
Lupin gets USFDA nod for scalp solution Pharma Major Lupin announced that it has received final approval from the US Food & Drug Administration to market a generic version of Dovonex Scalp Solution from Leo Pharmaceutical Products Ltd. Calcipotriene Topical Solution is indicated for the topical treatment of chroni...
Sun Pharma’s eye drug application accepted by USFDA Sun Pharmaceutical Industries Ltd said the US FDA has accepted a New Drug Application (NDA) for its OTX-101 dry eye drug. The application will now be processed for approval. Dry eye is a condition in which the eye does not produce tears properly, or when the tears are not of t...
Suven gets neuro drug patents in India, Canada Suven Life Sciences Ltd said it has been granted one patent each in Canada and India for drugs for treating Neurodegenerative diseases. The Canadian patent 2932428 is valid through 2034 and the Indian patent 289123 is valid through 2028. The chemical entities are consider...
Tata Teleservices shareholders to get 1 Bharti Airtel share for 2014 held Shareholders of Tata Teleservices Maharashtra Ltd -- the listed unit of Tata Tele -- will get one share of Bharti Airtel for every 2,014 shares held by them, the company said. The ratio of share issue indicates that the consumer mobile business of Tata Telservices Maharashtra...
Bharti Airtel buys Tigo Rwanda from Millicom International Bharti Airtel Limited said it has agreed to acquire 100% of Tigo Rwanda Limited, the local unit of Millicom International Cellular S.A.. Airtel already has operations in Rwanda and the acquisition "will consolidate the Rwandan telecom market and position Airtel as a strong nu...
TV Today to merge Mail Today with itself for synergy Broadcasting company TV Today Network said it has decided to write off nearly Rs 273 cr of accumulated losses at its Mail Today newspaper business and merge it with the parent company for better synergies. TV Today Network runs one of India's most popular television network, i...
Lupin gets US approval for generic version of Bayer’s oral contraceptive Pharma Major Lupin said it got the approval of the US Food and Drug Administration to launch a generic version of Bayer's oral contraceptive Safyral. The branded version has annual sales of around $23 mln in the US. Lupin's product will be called Tydemy. The combination...
Torrent Pharma completes acquisition of Unichem’s branded India business Torrent Pharmaceuticals said it completed its previously announced acquisition of the branded formulation business of Unichem Laboratories for India and Nepal, including its Sikkim manufacturing facility. The deal was signed on 3rd November, 2017. With this, Torrent has ent...
Glenmark reports successful trial for nasal spray, to file NDA soon Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that its nasal spray Ryaltris met safety and efficacy goals in a Phase 3 clinical study in treating perennial allergic rhinitis. With the positive results, the company said it plans to submit an applica...
Neuland Laboratories acquires Hyderabad factory from Arch Pharma Pharma manufacturer Neuland Laboratories said it acquired a manufacturing plant located near Hyderabad from Arch Pharma Labs Limited. The facility is spread across 12 acres and has a capacity of about 197 KL, the company said. The plant was inspected by the USFDA in 2015, ...
Eris Lifesciences completes acquisition of Strides Shasun India generics ops Pharma company Eris LifeSciences said it has completed its purchase of the India branded generics of Strides Shasun for Rs 500 cr in cash. "We now wish to confirm that the transaction ahs achieved closure," said Eris Lifesciences. Last month, Strides Shasun said it was sel...
Crucial win for Biocon as FDA approves cancer biosimilar trastuzumab Biocon and its partner Mylan scored a key victory on Friday as the US Food & Drug Administration approved its cancer-treating biosimilar trastuzumab. "Mylan anticipates potentially being the first company to offer a biosimilar to Herceptin, as a result of Mylan's ability to s...
EU accepts Biocon, Mylan’s application for cancer biosimilar pegfilgrastim Indian pharma company Biocon and its partner Mylan said EU authorities have accepted for review their applications for approving cancer treating biosimilars trastuzumab and pegfilgrastim submitted after completing corrective actions. The applications were resubmitted last mo...